Amin Hilman Zulkifli, Sasaki Naoto, Hirata Ken-Ichi
Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. Department of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan. Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Acta Med Indones. 2017 Jan;49(1):63-68.
Atherosclerosis is a chronic inflammatory disorder involving innate and adaptive immunity process. Effector T cell (Teff) responses promote atherosclerotic disease, whereas regulatory T cells (Tregs) have been shown to play a protective role against atherosclerosis by down-regulating inflammatory responses which include multiple mechanisms. Compelling experimental data suggest that shifting the Treg/Teff balance toward Tregs may be a possible therapeutic approach for atherosclerotic disease, although the role of Tregs in human atherosclerotic disease has not been fully elucidated. In this review, we discuss recent advances in our understanding of the roles of Tregs and Teffs in experimental atherosclerosis, as well as human coronary artery disease.
动脉粥样硬化是一种涉及先天性和适应性免疫过程的慢性炎症性疾病。效应T细胞（Teff）反应会促进动脉粥样硬化疾病，而调节性T细胞（Tregs）已被证明可通过下调包括多种机制的炎症反应来对动脉粥样硬化起到保护作用。有力的实验数据表明，尽管Tregs在人类动脉粥样硬化疾病中的作用尚未完全阐明，但将Treg/Teff平衡向Tregs方向转变可能是治疗动脉粥样硬化疾病的一种可行方法。在这篇综述中，我们讨论了在理解Tregs和Teffs在实验性动脉粥样硬化以及人类冠状动脉疾病中的作用方面的最新进展。
